All Oncology News

The NCCN has added the combination of TTFields (Optune) and temozolomide (Temodar) to its guidelines for Category 1 treatment of newly diagnosed glioblastoma following maximal safe resection and completion of radiation therapy.

Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.

The FDA has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma.

Ann H. Klopp, MD, PhD, discusses optimizing the use of chemoradiation and the future of the treatment landscape in endometrial cancer.

Sunil Verma, MD, shares his insight on the approval of MYL-1401O, as well as his excitement for the future development of biosimilars across oncology.

The addition of atezolizumab to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer.

The FDA has granted a priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.

The Centers for Medicare & Medicaid Services has announced that it will cover diagnostic laboratory tests using Next Generation Sequencing for patients with advanced cancer.

Sara Hurvitz, MD, and Sunil Verma, MD, share their expert insight on the latest groundbreaking developments in HER2-positive breast cancer.

Atezolizumab in combination with cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer.

The addition of weekly carboplatin following surgery and radiation therapy did not improve freedom from locoregional relapse in patients with high-risk cutaneous head and neck squamous cell carcinoma.

Howard M. Sandler, MD, discusses the emergence of hypofractionation as a viable treatment approach for patients with prostate cancer.

Alan P. Venook, MD, discusses the significance of the findings of the international IDEA study investigating doses of FOLFOX for patients with colon cancer.

Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.

The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC.

Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.

Ani S. Balmanoukian, MD, discusses developments in genitourinary malignancies with promising immunotherapy breakthroughs in renal cell carcinoma and urothelial carcinoma.

Both prior chemotherapy and a dependence on glycolysis appear to reduce the potential to develop T cells into chimeric antigen receptor T-cell therapy.

Acquired HER2 mutations cause endocrine resistance in some patients with ER+/HER2-negative breast cancer.

The FDA has granted a breakthrough therapy designation to erdafitinib for the treatment of metastatic urothelial carcinoma.

Stephen J. Freedland, MD, shares his insight on how to counsel patients with prostate cancer on the benefits of leading a healthier life.

Heather Greene, NP, discusses the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting immune-related adverse events.

Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.

Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.

The FDA has put a clinical hold on a phase I/II study of axalimogene filolisbac plus durvalumab (Imfinzi) for the treatment of patients with cervical cancer or head and neck cancer.

Andrew Seidman, MD, focuses on his view of the increasing role of nurse practitioners in the outpatient setting and hospitalists in the inpatient setting.

Timothy J. Daskivich, MD, discusses the use of High-intensity focused ultrasound and other treatment strategies in the prostate cancer armamentarium.

Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.

The FDA has granted a priority review to pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Neoadjuvant therapy can eliminate both invasive and in situ carcinoma in up to 50% of patients, particularly when their subtypes are triple-negative disease or HER2-positive cancers.